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THE IMPACT OF DULOXETINE FOR THE
TREATMENT OF MAJOR DEPRESSIVE DISORDER
ON THE QUALITY OF LIFE IN DEPRESSION
SCALE
Robinson RL, Obenchain RL, Croghan TW
Eli Lilly and Company, Indianapolis, IN, USA
OBJECTIVE: Duloxetine hydrochloride, a potent and
balanced dual reuptake inhibitor of serotonin and 
norepinephrine, previously has been shown to be safe 
and efﬁcacious among patients with major depressive 
disorder, with efﬁcacy measured by the Hamilton Depres-
sion Scale (HAM-D17). Our analyses show that treat-
ment with duloxetine also has a favorable impact on
quality of life.
METHODS: Adult patients (N = 353) from multiple
centers throughout the United States were included in a
double-blind, placebo- and active comparator-controlled
clinical trial. Patients were randomized to duloxetine 
40mg/day (administered 20mg/BID), duloxetine 80mg/
day (administered 40mg/BID), paroxetine 20mg/day, or
placebo, and followed for eight weeks. The protocol
called for 3 repeated measures on the Quality of Life in
Depression Scale (QLDS). The QLDS is a 34 item patient-
reported, unidimensional, depression-speciﬁc measure,
with lower scores indicating greater quality of life
(increased capacity to satisfy one’s own needs). To make
area-under-the-curve comparisons, mixed-model estima-
tion with random patient slopes and intercepts was used
to singly impute missing values. Sensitivity analyses using
Prediction plus Resampled Residual (PpRR) bootstrap-
ping were used to verify that single imputation had not
biased estimates associated with repeated measurements
on either QLDS or HAM-D17.
RESULTS: Duloxetine 80mg/day consistently produced
the lowest repeated QLDS scores. After adjusting for
baseline differences, both duloxetine 80mg/day and
paroxetine 20mg/day produce signiﬁcantly lower (p =
0.0001) QLDS scores than placebo. But duloxetine 
80mg/day patients reported signiﬁcantly lower (p = 0.002
to 0.01) QLDS scores than paroxetine patients. Similar
signifance levels resulted when using HAM-D17 as the
outcome.
CONCLUSIONS: In an 8-week randomized clinical trial,
duloxetine 80mg/day improved patient-reported scores
on QLDS in a way that is highly consistent with the 
corresponding improvements in HAM-D17 clinical 
measures. As many items from the QLDS and HAM-D17
are correlated, the overlap between quality of life and
mood should be further investigated.
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1The MEDSTAT Group, Inc, Washington, DC, USA; 2VA Palo
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OBJECTIVE: To examine the relationship between self-
reported and clinically assessed quality of life (QoL)
among participants in the U.S. Schizophrenia Care and
Assessment Program (SCAP).
METHODS: Data reﬂect measures obtained at the 12-
month assessment period (n = 908). Clinical instruments
were the Quality of Life Scale (QLS), Montgomery-
Asberg Depression Rating Scale (MADRS), Positive 
and Negative Symptoms Scale (PANSS) and Abnormal
Involuntary Movement Scale (AIMS). Self-report data
were obtained from Life Satisfaction (LifeSat) scale and
Depression scale, component scales of the SCAP Health
Questionnaire. Cross-sectional regression analyses were
conducted.
RESULTS: Correlation between the subjective and objec-
tive scale totals and component items were signiﬁcant in
most instances with magnitudes ranging from 0.2 to 0.6.
Clinical rating of QLS was signiﬁcantly and inversely
impacted by PANSS (p < 0.001) and MADRS (p < 0.001).
Unlike QLS, self-reported LifeSat was impacted by
MADRS (p < 0.001) and not by symptoms (PANSS). The
magnitude of effect of MADRS was 38% greater on
LifeSat than on QLS. Two QLS sub-scales (common
objects and activities [COA] and interpersonal relations
[IPR]) exhibited a signiﬁcant relationship with LifeSat 
(p < 0.01 and p < 0.001, respectively). In the presence of
MADRS, however, signiﬁcance of clinical symptoms and
QLS subscales diminished and R-squared increased. 
Clinically assessed depression exhibited a signiﬁcant rela-
tionship (0.38; p < 0.001) to self-reported depression.
CONCLUSIONS: The relationship of self-report to 
clinical assessment is of particular interest for persons
with schizophrenia given the current climate of partici-
patory treatment planning and outcome milestone
achievement. These ﬁndings demonstrate several impor-
tant points: 1) participant self-reports and clinical assess-
ments exhibit signiﬁcant interrelation for both QoL and
depression; 2) clinical symptoms and side effects are not
important drivers of self-reported QoL; 3) level of depres-
sion is an important factor in patients’ own sense of life
satisfaction; and 4) depression scores exhibit a mediating
effect between psychiatric symptom presentation and 
valuation of quality of life.
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PSYCHOMETRIC EVALUATION OF THE
MODIFIED STRAIN IN NURSING CARE
ASSESSMENT SCALE
Ciesla G1, Frank L1, Kleinman L1, Brodaty H2, Rupnow M3
1MEDTAP International, Bethesda, MD, USA; 2University of
New South Wales, Sydney, Australia; 3Janssen Pharmaceutica
Products, L.P,Titusville, NJ, USA
OBJECTIVES: The objective of this study was to evalu-
ate the psychometric properties (reliability and validity)
of the Modiﬁed Strain in Nursing Care Assessment Scale
(M-NCAS), a 32-item scale for assessing dementia-related
behaviors and the extent of job burden caused by those
behaviors.
